Mr. Hugh Rogers reports

BIONXT SIGNS LETTER AGREEMENT TO ACQUIRE 100% INTEREST IN IP AND TO CODEVELOP A SUBLINGUAL DRUG FORMULATION FOR CHEMOTHERAPY AND IMMUNOSUPPRESSANT TREATMENTS

Bionxt Solutions Inc. has signed a letter agreement with a European-based chemotherapy company (the co-developer) for the exclusive intellectual property rights to a novel sublingual drug formulation using a high-potency active pharmaceutical ingredient for oncology and immunosuppressant treatments.

Bionxt and the co-developer will work together to plan and manage the project, including prototype development, IP filings, preclinical and clinical studies, and regulatory filings. One hundred per cent of intellectual property rights will be assigned to Bionxt and the co-developer will receive a 20-per-cent royalty on licence fees paid to Bionxt from third party licensees, capped at $50-million (U.S.) in aggregate royalty payments. Bionxt and the co-developer are working toward a definitive IP and collaboration agreement to be signed in the next 60 days.

"This chemotherapy and immunosuppressant product opportunity is an excellent complement to our lead development program, which is a sublingual thin-film formulation of cladribine for multiple sclerosis," said Hugh Rogers, chief executive officer of Bionxt Solutions. "We expect to file provisional patents for our new sublingual product by year-end, which will expand our growing intellectual property portfolio and product pipeline."

The immunosuppressant market is growing rapidly due to a surge in organ transplants and autoimmune disorders. Statista estimates that the global market for immunosuppressants will reach $61.05-billion (U.S.) in 2025.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and Oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTC (over-the-counter) market under the symbol BNXTF and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.